Cargando…
Expanding the molecular spectrum of tenosynovial giant cell tumors
BACKGROUND: While great advances in clinical and pathological description of tenosynovial giant cell tumors (TGCT) have been made, TGCT molecular heterogeneity represents an ongoing challenge. The canonical oncogenic fusion CSF1::COL6A3 is not systematically observed, suggesting that other oncogenic...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691341/ https://www.ncbi.nlm.nih.gov/pubmed/36439507 http://dx.doi.org/10.3389/fonc.2022.1012527 |
_version_ | 1784837019950645248 |
---|---|
author | Gauduchon, Thibault Vanacker, Helene Pissaloux, Daniel Cassier, Philippe Dufresne, Armelle Karanian, Marie Meurgey, Alexandra Bouhamama, Amine Gouin, François Ray-Coquard, Isabelle Blay, Jean-Yves Tirode, Franck Brahmi, Mehdi |
author_facet | Gauduchon, Thibault Vanacker, Helene Pissaloux, Daniel Cassier, Philippe Dufresne, Armelle Karanian, Marie Meurgey, Alexandra Bouhamama, Amine Gouin, François Ray-Coquard, Isabelle Blay, Jean-Yves Tirode, Franck Brahmi, Mehdi |
author_sort | Gauduchon, Thibault |
collection | PubMed |
description | BACKGROUND: While great advances in clinical and pathological description of tenosynovial giant cell tumors (TGCT) have been made, TGCT molecular heterogeneity represents an ongoing challenge. The canonical oncogenic fusion CSF1::COL6A3 is not systematically observed, suggesting that other oncogenic mechanisms are involved in tumorigenesis. This study aims to explore by RNA sequencing a retrospective series of tumors diagnosed as TGCT, in order to provide a better description of their molecular landscape and to correlate molecular features with clinical data. METHODS: We analyzed clinicopathological data and performed whole-exome RNA sequencing on 41 TGCT samples. RESULTS: RNAseq analysis showed significant higher CSF1 and CSF1-R expression than a control panel of 2642 solid tumors. RNA sequencing revealed fusion transcripts in 14 patients including 6 not involving CSF1 and some previously unreported fusions. Unsupervised clustering on the expression profiles issued from this series suggested two distinct subgroups: one composed of various molecular subtypes including CSF1 and FN1 rearranged samples and one composed of four tumors harboring an HMGA2::NCOR2 fusion, suggesting distinct tumor entities. Overall, 15 patients received at least one systemic anti-CSF1R treatment and clinical improvement was observed in 11 patients, including patients from both clusters. DISCUSSION: This study reported molecular heterogeneity in TGCT, contrasting with the clinical and pathological homogeneity and the ubiquitous high CSF1 and CSF1R expression levels. Whether molecular diversity may impact the efficacy of systemic treatments needs to be further investigated. |
format | Online Article Text |
id | pubmed-9691341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96913412022-11-25 Expanding the molecular spectrum of tenosynovial giant cell tumors Gauduchon, Thibault Vanacker, Helene Pissaloux, Daniel Cassier, Philippe Dufresne, Armelle Karanian, Marie Meurgey, Alexandra Bouhamama, Amine Gouin, François Ray-Coquard, Isabelle Blay, Jean-Yves Tirode, Franck Brahmi, Mehdi Front Oncol Oncology BACKGROUND: While great advances in clinical and pathological description of tenosynovial giant cell tumors (TGCT) have been made, TGCT molecular heterogeneity represents an ongoing challenge. The canonical oncogenic fusion CSF1::COL6A3 is not systematically observed, suggesting that other oncogenic mechanisms are involved in tumorigenesis. This study aims to explore by RNA sequencing a retrospective series of tumors diagnosed as TGCT, in order to provide a better description of their molecular landscape and to correlate molecular features with clinical data. METHODS: We analyzed clinicopathological data and performed whole-exome RNA sequencing on 41 TGCT samples. RESULTS: RNAseq analysis showed significant higher CSF1 and CSF1-R expression than a control panel of 2642 solid tumors. RNA sequencing revealed fusion transcripts in 14 patients including 6 not involving CSF1 and some previously unreported fusions. Unsupervised clustering on the expression profiles issued from this series suggested two distinct subgroups: one composed of various molecular subtypes including CSF1 and FN1 rearranged samples and one composed of four tumors harboring an HMGA2::NCOR2 fusion, suggesting distinct tumor entities. Overall, 15 patients received at least one systemic anti-CSF1R treatment and clinical improvement was observed in 11 patients, including patients from both clusters. DISCUSSION: This study reported molecular heterogeneity in TGCT, contrasting with the clinical and pathological homogeneity and the ubiquitous high CSF1 and CSF1R expression levels. Whether molecular diversity may impact the efficacy of systemic treatments needs to be further investigated. Frontiers Media S.A. 2022-11-10 /pmc/articles/PMC9691341/ /pubmed/36439507 http://dx.doi.org/10.3389/fonc.2022.1012527 Text en Copyright © 2022 Gauduchon, Vanacker, Pissaloux, Cassier, Dufresne, Karanian, Meurgey, Bouhamama, Gouin, Ray-Coquard, Blay, Tirode and Brahmi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Gauduchon, Thibault Vanacker, Helene Pissaloux, Daniel Cassier, Philippe Dufresne, Armelle Karanian, Marie Meurgey, Alexandra Bouhamama, Amine Gouin, François Ray-Coquard, Isabelle Blay, Jean-Yves Tirode, Franck Brahmi, Mehdi Expanding the molecular spectrum of tenosynovial giant cell tumors |
title | Expanding the molecular spectrum of tenosynovial giant cell tumors |
title_full | Expanding the molecular spectrum of tenosynovial giant cell tumors |
title_fullStr | Expanding the molecular spectrum of tenosynovial giant cell tumors |
title_full_unstemmed | Expanding the molecular spectrum of tenosynovial giant cell tumors |
title_short | Expanding the molecular spectrum of tenosynovial giant cell tumors |
title_sort | expanding the molecular spectrum of tenosynovial giant cell tumors |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691341/ https://www.ncbi.nlm.nih.gov/pubmed/36439507 http://dx.doi.org/10.3389/fonc.2022.1012527 |
work_keys_str_mv | AT gauduchonthibault expandingthemolecularspectrumoftenosynovialgiantcelltumors AT vanackerhelene expandingthemolecularspectrumoftenosynovialgiantcelltumors AT pissalouxdaniel expandingthemolecularspectrumoftenosynovialgiantcelltumors AT cassierphilippe expandingthemolecularspectrumoftenosynovialgiantcelltumors AT dufresnearmelle expandingthemolecularspectrumoftenosynovialgiantcelltumors AT karanianmarie expandingthemolecularspectrumoftenosynovialgiantcelltumors AT meurgeyalexandra expandingthemolecularspectrumoftenosynovialgiantcelltumors AT bouhamamaamine expandingthemolecularspectrumoftenosynovialgiantcelltumors AT gouinfrancois expandingthemolecularspectrumoftenosynovialgiantcelltumors AT raycoquardisabelle expandingthemolecularspectrumoftenosynovialgiantcelltumors AT blayjeanyves expandingthemolecularspectrumoftenosynovialgiantcelltumors AT tirodefranck expandingthemolecularspectrumoftenosynovialgiantcelltumors AT brahmimehdi expandingthemolecularspectrumoftenosynovialgiantcelltumors |